A recent study conducted on melanoma cells revealed that increased expression of PTENP1-AS led to the induction of cell resistance to BRAF inhibitors, which may be due to the employment of epigenetic modifiers in the PTEN promoter region, resulting in decreased expression of PTEN [63], and in samples from stage III melanoma patients, high levels of PTENP1-AS were noted and associated with decreased survival [63]. This evidence concerns the gene PTENP1 and melanoma.